rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Decision Support for Heart Failure Prescribing
Status: Not yet recruiting

Clinical decision support (CDS) tools can 'nudge' clinicians to make the best decisions easy. Although required by "meaningful use" regulations, more than 40% of CDS lead to no change and the remaining lead to improvements that are modest at best. This is because CDS tools often ignore contextual factors and present irrelevant information. Although many tools have undergone patient-specific optimization, 'traditional CDS' are rarely clinician-specific. For example, a traditional CDS tool for beta blockers and heart failure with reduced ejection fraction (HFrEF) addresses common prescribing misconceptions by stating asthma is not a contraindication and providing a safe threshold for blood pressure. For clinicians without these misconceptions, these statements are irrelevant and distract from key information. A 'personalized CDS' would evaluate clinician past prescribing patterns to determine whether prescribing misconceptions might exist and then conditionally present information to address those misconceptions. The objective of this research is to create personalized clinician-specific CDS that overcome shortcomings of traditional CDS. The central hypothesis is a personalized CDS that minimizes irrelevant information will lead to a higher rate of prescribing guideline-directed management and therapy (GDMT) for HFrEF compared to a traditional CDS.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The study subjects are potential users of the CDS, specifically clinicians with prescribing privileges who practice at one of the health system's (UCHealth) outpatient cardiology or primary care clinics. Because we are observing their prescribing behaviors, we are also evaluating patient characteristics which could influence their prescribing decisions.  Exclusion Criteria:  Clinicians who do not practice in cardiology or primary care clinics or do not practice within UCHealth system. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 89 Years - StdAgeList: Adult, Older Adult
Application of the Web-based Acceptance and Commitment Therapy for Depression
Status: Recruiting

PROSPECTIVE INTERVENTION STUDY; EFFICACY OF WEB-BASED ACCEPTANCE AND COMMITMENT THERAPY

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients who diagnosed major depressive disorder  Exclusion Criteria:  Patients who have serious medical problems, metal implants in their bodies, severe brain injury or brain disease Women who were pregnant or nursing Patients at high risk for suicide - HealthyVolunteers: No - Gender: All - MinimumAge: 19 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
Status: Recruiting

This is a Phase 1, open-label, non-randomized, fixed sequence study designed to evaluate the effect of ECC5004 on single dose pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in healthy participants.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male and female participants of non-childbearing potential (NCBP) between the ages of 18 to 65 years of age BMI of 18.0 to 32.0 kg/m2 Female participants who are postmenopausal, confirmed by FSH test, or surgically sterile, confirmed by medical documentation, or agree to practice true abstinence Male participants agree to use contraception, or agree to practice true abstinence No clinically significant findings in physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, clinical laboratory evaluations, concomitant medications, or medical/psychiatric history Able to understand and sign and date informed consent  Exclusion Criteria:  Females who are pregnant, planning to become pregnant, or breastfeeding during the study or within 3 months after the study Concomitant participation in any investigational study of any nature Blood loss of non-physiological reasons ≥ 200 ml (i.e., trauma, blood collection, blood donation) within 2 months prior to the first dose of study treatment, or plan to donate blood during this trial and within 1 month after the last dose of study treatment Serum calcitonin > 20 ng/L Clinically relevant acute or chronic medical conditions or diseases of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic systems Individual or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia 2 (MEN2), or suspected MTC History of pancreatitis Significant allergic reaction to active ingredients or excipients of the study drug Any clinically significant abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol test, or medical history which in the opinion of the Investigator would prevent the participants from participating in the study Used or plan to use any drugs or substances that can modulate the activity of CYP3A4 within at least 14 days prior to the first dose of study treatment until after their final follow up visit Use of drugs with enzyme-inducing properties such as St. John's Wort within 3 weeks prior to the first dose of study treatment until after their final follow up visit - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)
Status: Recruiting

The investigators propose a randomized controlled trial comparing BP and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length versus current standard practice using fixed lengths. The findings would provide further insight into feasibility of standardizing RYGB limb lengths and optimizing resultant weight loss and metabolic effects. The investigators hypothesize RYGB with ratio-adjusted limb lengths (aRYGB) will result in higher total weight loss and resolution of metabolic syndrome comorbidities, including diabetes, hyperlipidemia, and hypertension compared to standard fixed-length RYGB (sRYGB). The study will also utilize the Short Form Rand 36-Item Health Survey (SF36) to determine differences in postoperative quality of life metrics.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  morbidly obese patients (defined by BMI between 40 and 60). Patient who understands and accepts the need for a long-term follow-up. Patient who agrees to be included in the study  Exclusion Criteria:  individuals unable to understand and sign a written consent form patients with history of previous bariatric surgery procedures presence of a severe and evolutive life threatening pathology unrelated to obesity previous gastric or small bowel resection active cancer pregnancy or desired to be pregnant during the study mentally unbalanced patients under supervision or guardianship, patient unable to give consent - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes
Status: Recruiting

Alpha-melanocyte stimulatory hormone (α-MSH) is a melanocyte-stimulating hormone produced by the hypothalamus and released from the pituitary gland. It acts as an agonist to the melanocortin 5 receptor (MC5R) in human skeletal muscle, playing a role in glucose uptake and disposal. This study aims to investigate whether α-MSH can enhance glucose tolerance in patients with Type 2 Diabetes Mellitus (T2DM).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  People with T2DM treated with oral or injectable medications which have been stable for 3 months, but not insulin therapy for type 2 diabetes. Stable body weight and HbA1c for at least 3 months The participant is capable of giving written informed consent The participant is able to read, comprehend and record information written in English  Exclusion Criteria:  Previous or current psychiatric diagnosis listed in DSM-V Axis 1. Significant current or past medical or psychiatric history that, in the opinion of the investigators, contraindicates their participation. History of type 1 diabetes mellitus. History of endocrine disorder. History of ischaemic heart disease, hypertension (current BP > 160/95 mmHg), heart failure, cardiac arrhythmia, peripheral vascular or cerebrovascular disease. History or presence of significant respiratory, gastrointestinal, hepatic, oncological, neurological or renal disease or other condition that in the opinion of the Investigators may affect participant safety or outcome measures. Unwillingness or inability to follow the procedures outlined in the protocol. History of sensitivity to any of the peptides, or components thereof, or a history of drug or other allergy that, in the opinion of the investigators, contraindicates their participation. Use of current regular prescription or over-the-counter medications that in the opinion of the Investigators may affect participant safety or outcome measures. Clinically significant abnormalities in screening electrocardiogram (ECG) or blood tests abnormalities which in the opinion of the study physician, is clinically significant and represents a safety risk. Current pregnancy or breast-feeding in female participants (the investigators would advise using contraception for the duration of the study). Pulse rate <40 or >100 beats per minute OR systolic blood pressure >160 and <100 and a diastolic blood pressure >95 and <50 in the semi-supine position. The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first experimental visit in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). Exposure to more than 3 new investigational medicinal products within 12 months prior to the screening. Participants who have donated, or intend to donate, blood within three months before the screening visit or following study visit completion. - HealthyVolunteers: No - Gender: All - MinimumAge: 21 Years - MaximumAge: 50 Years - StdAgeList: Adult
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Status: Not yet recruiting

This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Aged 18 and older. Capable of giving signed informed consent. Diagnosed with particular disease characteristics. Expected survival ≥ 3 months. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. A female patient is eligible to participate if she is not pregnant or breastfeeding. A male patient is eligible to participate if he agrees to remain abstinent or use a male condom when having sexual intercourse with a WOCBP, or if he has had a bilateral vasectomy. Have measurable disease by revised RECIST v1.1 criteria.  Exclusion Criteria:  Inability to take oral medications or gastrointestinal abnormalities potentially impacting absorption. Current enrollment or past participation in another clinical trial. Unresolved adverse reactions (except alopecia) from previous cancer-directed therapy. Use of cancer-directed therapies, including chimeric antigen receptor T cell therapy. Autologous transplantation within 60 days. Prior allogeneic transplantation. Major surgery within 30 days, or unresolved complications after a major or minor surgery. History of or currently active cardiovascular disease. Clinically significant respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders. History of other malignancy. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor
Status: Recruiting

The purpose of this study is to collect electrophysiological data related to functional brain network changes in patients undergoing deep brain stimulation for the treatment of essential tremor. Participants will be asked to remain seated with their head inside of a Magnetoencephalography (MEG) recording system as resting-state and task-related data are acquired. Spontaneous electrophysiological activity will be recorded in both the eyes open and eyes closed conditions with the participant seated comfortably. These recordings will be repeated in the DBS OFF and DBS ON states, with the ON state involving specific settings identified as optimal, sub-optimal, or ineffective at achieving tremor control. They will also be repeated following the optional administration non-DBS tremor mitigation techniques, which may include one or more of 1) cooling the limb, 2) oral administration of alprazolam, 3) oral consumption of ethanol (alcohol), or 4) peripheral nerve stimulation.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Between 40 and 80 years of age; Ability to provide informed consent; Clinical diagnosis of ET by a movement disorders neurologist with a disease duration of at least 3 years and being treated with a DBS; OR Clinical diagnosis of ET by a movement disorders neurologist with a disease duration of at least 3 years and not being treated with a DBS; OR No known neurological disease or disorder.  Exclusion Criteria:  Secondary Parkinsonism, stroke, or progressive central nervous system disease other than ET; Presence of active psychiatric symptoms meeting Diagnostic and Statistical Manual of Mental Disorders-4th Edition (DSM-IV) criteria for Axis-I disorder on formal psychiatric evaluation other than depression or anxiety. History of cognitive impairment meeting Diagnostic and Statistical Manual of Mental Disorders-4th Edition (DSM-IV) criteria for dementia on formal neuropsychological evaluation, as documented in chart; Lack of English-language fluency which would interfere with the ability to understand the study consenting process and potential study risks; Hearing or visual impairment precluding testing; Motor impairment impacting test responses (i.e., orthopedic injury or disease). Anyone currently taking medications with Antabuse-like effects will be excluded from any alcohol administration. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 40 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Participants will be selected from the known patient population from a large research medical center located in a medium-to-large American city. - SamplingMethod: Non-Probability Sample
Effect of Scapular Stabilization Exercises Versus Virtual Reality Exercises in Basketball Players With Scapular Dyskinesia
Status: Not yet recruiting

this study will be conducted to compare virtual reality and scapular stabilizing exercise among basketball player with scapular dyskinesia on scapular muscle performance, rounded shoulder, pain intensity , disability and hand grip strength

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  ninety basketball players of both genders. Subjects with age between 20 and 25 years old. Subjects with Body Mass Index (BMI) ranging from 18 to 25 kg/m².  Exclusion Criteria:  An injury within the four weeks before testing. Upper extremity fractures. Bilateral repetitive strain injuries Osteoarthritis on hand - HealthyVolunteers: No - Gender: All - MinimumAge: 20 Years - MaximumAge: 25 Years - StdAgeList: Adult
Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery
Status: Recruiting

The aim of this study is to compare between peribulbar block and subtenon block as an adjunct to general anesthesia in children undergoing strabismus surgery on oculocardiac reflex (OCR), post-operative analgesia and postoperative vomiting. Both techniques will be compared to intra-operative intravenous (IV) paracetamol combined with general anesthesia as a sole anesthetic technique.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Participants were children (6-13 years), ASA I-II patients, scheduled to undergo strabismus surgery.  Exclusion Criteria:  Children with tumors or infections of the orbit, raised intraocular pressure more than 20 mm Hg, axial length more than 28 mm, eye injury, airway abnormalities or who were blind in the eye other than that which was to be operated on were excluded. Other exclusion criteria included patients undergoing revision surgery, known allergy to local anesthetics or non-steroidal antiinflammatory drugs (NSAIDs), steroid therapy, parental refusal to participate and patients with INR more than 1.5 or with platelets less than 100. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 6 Years - MaximumAge: 13 Years - StdAgeList: Child
Microphthalmia, Anophthalmia, and Coloboma Genetic Epidemiology in Children
Status: Recruiting

The investigators are inviting families to take part in a research study that will help us better understand the physical characteristics associated with children who have Microphthalmia, Anophthalmia, and Coloboma (MAC) and how changes in their DNA sequence, called genetic mutations, play a role in the risk of developing MAC

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  All MAC cases Parents of the above children. Siblings of the above children. English or Spanish speaking.  Exclusion Criteria:  All subjects who do not meet the inclusion criteria listed above. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Children diagnosed with congenital microphthalmia, anophthalmia, or coloboma (without a recognized syndrome). - SamplingMethod: Non-Probability Sample
Thyroid Dysfunction in Patients With Major Psychiatric Disorders
Status: Not yet recruiting

Thyroid dysfunction in major psychiatric disorders in psychiatric patients admitted to psychiatric unit of assiut university hospital

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  patients with major psychiatric disorders admitted to psychiatric unit of neuropsychiatry department of Assiut university hospital in Egypt.  Exclusion Criteria:  pregnant or lactating females Patients on estrogen therapy or contraceptive Patients on carbamazepine, oxcarbazepine, phenytoin - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with mental illness, diagnosed based on DSM 5-TR and whose condition is severe enough to require admission in the psychiatric ward. - SamplingMethod: Probability Sample
Clinical and Radiographic Success Rate of Pulpotomy Versus Pulpectomy for Management of Primary Teeth With Deep Caries
Status: Not yet recruiting

This trial aims to compare treatment outcomes between Pulpotomy and Pulpectomy in treating vital primary teeth diagnosed with deep caries with symptoms of irreversible pulpits

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Aged 4 to 6 years , in good general health The parents provided written informed consent. Clinical characteristics, defined as spontaneous pain and the presence of a deep carious lesion with pulp exposure and bleeding that did not halt within five minutes following removal of the coronal pulp tissue. Restorable teeth.  Exclusion Criteria:  With systemic disease. Physical or mental disability. Unable to attend follow-up visits. Refusal of participation. Previously accessed teeth. Swelling, tenderness to percussion or palpation, or pathological mobility. Pre-operative radiographic pathology such as resorption (internal or external), per-radicular or furcation radiolucency. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 4 Years - MaximumAge: 6 Years - StdAgeList: Child
mHealth Behavioural Intervention to Increase Breast Cancer Screening Rates Among Members of the Public
Status: Not yet recruiting

Late-stage presentation of breast cancer cases are on the rise in Malaysia. Encouraging breast screening practices can assist in early breast cancer detection. Literature has proven that behavior interventions in the form of behavior change health communication using social messaging applications is a viable strategy and potentially effective at motivating breast cancer screening among the public. Such studies are scarce in the South East Asian region, particularly in Malaysia, which is the prime motivation for the current study,

Based on this promising prospect, we designed a randomized controlled trial to study the effects of applying persuasive health communication materials to initiate behavior change among a group of Malaysian women. Materials are delivered in the form of a health communication program over a social messaging application to promote breast cancer screening practices, which is either a clinical breast examination, or a mammogram. We hypothesize that Malaysian women who are exposed to such materials that are designed based on behavior science and behavior change principles will be nudged and hence more likely to attend breast cancer screening compared to a control group.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Malaysian women aged 40 years and above Possess a smartphone with the predetermined social messaging application (derived from Phase 1 of study) installed. Have not been diagnosed with cancer before.  Exclusion Criteria:  Underwent Clinical Breast Examination in the past 12 months. Mammogram screening in the past 2 years. Subjects who are deemed to have cognitive impairment and unable to provide consent to the study. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 40 Years - StdAgeList: Adult, Older Adult
Incidence of Cut-out Using Intramedullary Nails With Double Cephalic Screw vs. Unique in Pertrochanteric Fractures
Status: Not yet recruiting

The goal of this clinical trial is to compare outcomes in the treatment of proximal femur fractures. The main question it aims to answer is whether the use of a double cephalic screw prevents nail failure (cut-out).

Participants will be treated using open reduction and internal fixation with a proximal femoral nail. Researchers will compare intramedullary nailing with a single cephalic screw (Gamma nail) and with a double cephalic screw (Chimaera nail) to see the cut-out rate.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients with proximal femur fracture (OTA/AO 31-A1, A2 and A3) requiring surgical treatment. Signing of written informed consent according to current legislation before collecting any information, either by the patient or by the legal representative or by people linked by family ties.  Exclusion Criteria:  Presence of other fractures in the ipsilateral femur that condition the surgical treatment of the pertrochanteric femur fracture. Subcapital fracture of the proximal femur. Subtrochanteric fracture of the proximal femur. Pathological fracture. - HealthyVolunteers: No - Gender: All - MinimumAge: 70 Years - StdAgeList: Older Adult